Fitch: Novartis's Acquisition Highlights Diversification Outside Pharma - Press Release - 2009/05/20 - Fitch Research

Report title: Fitch: Novartis's Acquisition Highlights Diversification Outside Pharma

from Fitch Research
427 word report published May 20, 2009

Price $85.00 available for immediate download

Report Overview

Search Inside

About Fitch Research

Fitch: Novartis's Acquisition Highlights Diversification Outside Pharma 20 May 2009 5:04 AM (EDT) Fitch Ratings-London/Chicago-20 May 2009: Fitch Ratings says Novartis' acquisition of EBEWE Pharma, a privately held Austrian generic drugs...

Report Type:

Press Release

Company(ies):

Novartis AG

Ticker(s):

NOVN

Free Sample:

Click Here to Download

Format:

HTML

Enter the keyword(s) which you would like to search for within this document and click "Search"

Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.

Also from Fitch Research

Fitch: European Pharma Faces Declining Profitability on Diversification Pressures $85.00
Novartis AG $165.00
Fitch: Limited Scale and Synergies Continue to Drive De-Coupling Trend in Pharma-Chemicals Industry $85.00
Global Pharmaceutical R&D Pipeline (Second-Quarter 2009) $275.00
Global Pharmaceutical R&D Pipeline (First-Quarter 2009) $275.00
Global Pharmaceutical R&D Pipeline (Fourth-Quarter 2008) $275.00
Fitch Global Pharmaceutical R&D Quarterly: 4th Qtr Regulatory Approvals Add to '08 Increases $85.00
Novartis AG $425.00

Price: $85.00

Free Sample

Questions about
this research?

Send page to a friend

Return to
Alacra Industry Snapshot

Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.